Combined Treatment of an Intratumoral Injection of Dendritic Cells and Systemic Chemotherapy (Paclitaxel) for Murine Fibrosarcoma.
10.3349/ymj.2005.46.6.835
- Author:
Gwang Seong CHOI
1
;
Moon Hee LEE
;
Soon Ki KIM
;
Chul Soo KIM
;
Hong Sik LEE
;
Moon Whan IM
;
Hye Yun KIL
;
Do Hwan SEONG
;
Jong Rok LEE
;
Woo Chul KIM
;
Min Geol LEE
;
Sun U SONG
Author Information
1. Department of Dermatology, Inha University College of Medicine, Inchon, Korea.
- Publication Type:Original Article ; Evaluation Studies ; Research Support, Non-U.S. Gov't
- Keywords:
Dendritic cells;
paclitaxel;
immunotherapy
- MeSH:
Treatment Outcome;
Transplantation, Isogeneic;
Phenotype;
Paclitaxel/administration & dosage/*therapeutic use;
Mice;
Injections, Intraperitoneal;
Immunologic Memory;
Fibrosarcoma/drug therapy/pathology/*therapy;
Dendritic Cells/cytology/*transplantation;
Combined Modality Therapy;
Cells, Cultured;
Cell Line, Tumor;
Bone Marrow Cells/cytology;
Antineoplastic Agents, Phytogenic/administration & dosage/*therapeutic use;
Animals
- From:Yonsei Medical Journal
2005;46(6):835-842
- CountryRepublic of Korea
- Language:English
-
Abstract:
A novel combined treatment of conventional chemotherapy with an intratumoral injection of syngeneic dendritic cells (DCs) has emerged as a potent cancer treatment strategy. In this study, we evaluated the synergistic effect of an intraperitoneal (i.p.) injection of a chemotherapeutic drug, paclitaxel, and an intratumoral (i.t.) injection of syngeneic bone marrow- derived DCs for the treatment of pre-existing fibrosarcoma. Subcutaneous tumors were established using MCA102 fibrosarcoma cells in syngeneic C57BL/6 mice. The results demonstrated that the combined treatment of paclitaxel chemotherapy and the injection of DCs led to complete tumor regression, in contrast to only partial eradication of the tumors with chemotherapy or DCs alone. Furthermore, the tumor-free mice were able to resist a repeat challenge with the same type of tumor. These findings suggest that a combination therapy of systemic chemotherapy along with the intratumoral administration of DCs is a potent treatment strategy for fibrosarcoma.
